Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 7/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.52 |
| ▸ | MMP2 | P08253 | 8/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19015948 | 0.87 | NPY5R (0.49) | TDP1MMP9ADAMTS4MMP2KDM4E | |
| SCHEMBL7890390 | 0.87 | ADAMTS4 (0.57) | MMP9ADAMTS4MMP2KDM4EGFER | |
| SCHEMBL18473182 | 0.87 | ADAMTS4 (0.57) | MMP9ADAMTS4MMP2KDM4EGFER | |
| SCHEMBL19015758 | 0.84 | KDM4E (0.53) | ADAMTS4MMP2KDM4EGFERALDH1A1 | |
| SCHEMBL19015893 | 0.83 | KDM4E (0.55) | ADAMTS4KDM4EGFERALDH1A1 | |
| SCHEMBL19407479 | 0.83 | KDM4E (0.52) | ADAMTS4KDM4EGFERALDH1A1MAPT | |
| SCHEMBL21458999 | 0.83 | KDM4E (0.52) | ADAMTS4KDM4EGFERALDH1A1MAPT | |
| SCHEMBL29858116 | 0.83 | KDM4E (0.52) | ADAMTS4KDM4EGFERALDH1A1MAPT | |
| SCHEMBL16058523 | 0.80 | TDP1 (0.58) | TDP1MMP9ADAMTS4MMP2MMP3 | |
| SCHEMBL21885546 | 0.80 | TDP1 (0.58) | TDP1MMP9ADAMTS4MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2019-01-01 | — | — | US | disclosed |
| EP-2288615-B1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-06-21 | — | — | EP | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8791235-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791235-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2011-03-31 | — | — | US | disclosed |
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2011-03-31 | — | — | US | disclosed |
| WO-2010133000-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009140765-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | CASP3, CASP1, HTRA2 | TDP1 844/4885MMP9 145/4885ADAMTS4 322/4885 |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, HTRA2 | TDP1 844/4885MMP9 145/4885ADAMTS4 322/4885 |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | TDP1 629/4885MMP9 128/4885ADAMTS4 166/4885 |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | TDP1 582/4885MMP9 91/4885ADAMTS4 208/4885 |
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | TDP1 582/4885MMP9 91/4885ADAMTS4 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.